Evidence Based Medicine on FHIR Implementation Guide
2.0.0-ballot - ballot International flag

Evidence Based Medicine on FHIR Implementation Guide, published by HL7 International / Clinical Decision Support. This guide is not an authorized publication; it is the continuous build for version 2.0.0-ballot built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/HL7/ebm/ and changes regularly. See the Directory of published versions

: ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria - XML Representation

Raw xml | Download


<Group xmlns="http://hl7.org/fhir">
  <id value="279340"/>
  <meta>
    <versionId value="4"/>
    <lastUpdated value="2024-11-16T19:36:32.757Z"/>
    <profile
             value="http://hl7.org/fhir/uv/ebm/StructureDefinition/conceptual-cohort-definition"/>
  </meta>
  <text>
    <status value="extensions"/>
    <div xmlns="http://www.w3.org/1999/xhtml"><p class="res-header-id"><b>Generated Narrative: Group 279340</b></p><a name="279340"> </a><a name="hc279340"> </a><a name="279340-en-US"> </a><div style="display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%"><p style="margin-bottom: 0px">version: 4; Last updated: 2024-11-16 19:36:32+0000</p><p style="margin-bottom: 0px">Profile: <a href="StructureDefinition-conceptual-cohort-definition.html">ConceptualCohortDefinition</a></p></div><p><b>Artifact Author</b>: Brian S. Alper: </p><p><b>Artifact related artifact</b>: No display for RelatedArtifact  (type: cite-as; citation: CohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 279340. Revised 2024-09-29. Available at: https://fevir.net/resources/Group/279340. Computable resource at: https://fevir.net/resources/Group/279340.)</p><p><b>url</b>: <a href="https://fevir.net/resources/Group/279340">https://fevir.net/resources/Group/279340</a></p><p><b>identifier</b>: FEvIR Object Identifier/https://fevir.net/FOI/279340</p><p><b>title</b>: ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria</p><p><b>status</b>: Active</p><p><b>publisher</b>: Computable Publishing LLC</p><p><b>contact</b>: <a href="mailto:support@computablepublishing.com">support@computablepublishing.com</a></p><p><b>description</b>: </p><div><p>Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
a. T1DM-specific criteria
..i. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria
..ii. have been on the following daily insulin therapy for at least 1 year
...1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or
...2) continuous subcutaneous insulin infusion (CSII)
..iii. are between 18 and 64 years old at the time of informed consent
..iv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening
b. T2DM-specific criteria
..i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria
..ii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year
...1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII
...2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine
..iii. are between 20 and 70 years old at the time of informed consent
..iv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening</p>
</div><p><b>copyright</b>: </p><div><p>https://creativecommons.org/licenses/by-nc-sa/4.0/</p>
</div><p><b>membership</b>: Conceptual</p><p><b>combinationMethod</b>: Any of</p><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by Reference</span></p><p><b>value</b>: <a href="Group-279347.html">CohortDefinition: T1DM-specific criteria</a></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>T1DM-specific criteria
i. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria
ii. have been on the following daily insulin therapy for at least 1 year
..1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or...2) continuous subcutaneous insulin infusion (CSII)
iii. are between 18 and 64 years old at the time of informed consent
iv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening</p>
</div></blockquote><blockquote><p><b>characteristic</b></p><p><b>code</b>: <span title="Codes:">Defined by Reference</span></p><p><b>value</b>: <a href="Group-279346.html">CohortDefinition: T2DM-specific criteria</a></p><p><b>exclude</b>: false</p><p><b>description</b>: </p><div><p>T2DM-specific criteria
i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria
ii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year
..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII
..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine
iii. are between 20 and 70 years old at the time of informed consent
iv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening</p>
</div></blockquote></div>
  </text>
  <extension url="http://hl7.org/fhir/StructureDefinition/artifact-author">
    <valueContactDetail>
      <name value="Brian S. Alper"/>
    </valueContactDetail>
  </extension>
  <extension
             url="http://hl7.org/fhir/StructureDefinition/artifact-relatedArtifact">
    <valueRelatedArtifact>
      <type value="cite-as"/>
      <citation
                value="CohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria [Database Entry: FHIR Group Resource]. Contributors: Brian S. Alper [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 279340. Revised 2024-09-29. Available at: https://fevir.net/resources/Group/279340. Computable resource at: https://fevir.net/resources/Group/279340."/>
    </valueRelatedArtifact>
  </extension>
  <url value="https://fevir.net/resources/Group/279340"/>
  <identifier>
    <type>
      <coding>
        <system value="http://terminology.hl7.org/CodeSystem/v2-0203"/>
        <code value="ACSN"/>
        <display value="Accession ID"/>
      </coding>
      <text value="FEvIR Object Identifier"/>
    </type>
    <system value="urn:ietf:rfc:3986"/>
    <value value="https://fevir.net/FOI/279340"/>
    <assigner>
      <display value="Computable Publishing LLC"/>
    </assigner>
  </identifier>
  <title
         value="ConceptualCohortDefinition: Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria"/>
  <status value="active"/>
  <publisher value="Computable Publishing LLC"/>
  <contact>
    <telecom>
      <system value="email"/>
      <value value="support@computablepublishing.com"/>
    </telecom>
  </contact>
  <description
               value="Meet either T1DM-specific eligibility criteria or T2DM-specific eligibility criteria
a. T1DM-specific criteria
..i. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria
..ii. have been on the following daily insulin therapy for at least 1 year
...1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or
...2) continuous subcutaneous insulin infusion (CSII)
..iii. are between 18 and 64 years old at the time of informed consent
..iv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening
b. T2DM-specific criteria
..i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria
..ii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year
...1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII
...2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine
..iii. are between 20 and 70 years old at the time of informed consent
..iv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening"/>
  <copyright value="https://creativecommons.org/licenses/by-nc-sa/4.0/"/>
  <membership value="conceptual"/>
  <combinationMethod value="any-of"/>
  <characteristic>
    <code>
      <text value="Defined by Reference"/>
    </code>
    <valueReference>🔗 
      <reference value="Group/279347"/>
      <type value="Group"/>
      <display value="CohortDefinition: T1DM-specific criteria"/>
    </valueReference>
    <exclude value="false"/>
    <description
                 value="T1DM-specific criteria
i. Diagnosis of T1DM based on the World Health Organization (WHO) diagnostic criteria
ii. have been on the following daily insulin therapy for at least 1 year
..1) multiple daily injection of long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) and rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine), or...2) continuous subcutaneous insulin infusion (CSII)
iii. are between 18 and 64 years old at the time of informed consent
iv. have a body mass index of 18.5 to 30.0 kg/m2 at the time of screening"/>
  </characteristic>
  <characteristic>
    <code>
      <text value="Defined by Reference"/>
    </code>
    <valueReference>🔗 
      <reference value="Group/279346"/>
      <type value="Group"/>
      <display value="CohortDefinition: T2DM-specific criteria"/>
    </valueReference>
    <exclude value="false"/>
    <description
                 value="T2DM-specific criteria
i. Diagnosis of T2DM based on the World Health Organization (WHO) diagnostic criteria
ii. have received the following daily insulin therapy with or without oral anti-hyperglycemic medications (OAMs) for at least 1 year
..1) insulin: long-acting insulin analog (either insulin glargine [U-100 or U-300] or insulin degludec [U-100]) alone, or in combination with rapid-acting insulin analog (insulin lispro, insulin aspart, or insulin glulisine) or CSII
..2) OAM: up to 3 of the following OAMs in accordance with local regulations: metformin, dipeptidyl peptidase-4 inhibitor, sodium glucose cotransporter 2 inhibitor, sulfonylurea (should not be more than half of maximum approved doses), glinides, alpha-glucosidase inhibitor, or thiazolidine
iii. are between 20 and 70 years old at the time of informed consent
iv. have a body mass index of 18.5 to 35.0 kg/m2 at the time of screening"/>
  </characteristic>
</Group>